| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 0 | 169.418 | 609.223 | 1.369.909 |
| Total Income - EUR | - | - | - | - | - | - | 0 | 175.808 | 613.095 | 1.374.676 |
| Total Expenses - EUR | - | - | - | - | - | - | 12.399 | 122.757 | 399.458 | 1.128.611 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | -12.399 | 53.051 | 213.638 | 246.065 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | -12.399 | 51.797 | 196.658 | 244.677 |
| Employees | - | - | - | - | - | - | 0 | 3 | 8 | 29 |
Check the financial reports for the company - Reumavision Msk S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 113.427 | 252.140 | 331.338 | 566.112 |
| Current Assets | - | - | - | - | - | - | 5.593 | 30.885 | 87.778 | 700.898 |
| Inventories | - | - | - | - | - | - | 0 | 0 | 418 | 4.151 |
| Receivables | - | - | - | - | - | - | 0 | 12.118 | 64.768 | 404.977 |
| Cash | - | - | - | - | - | - | 5.593 | 18.768 | 22.593 | 291.770 |
| Shareholders Funds | - | - | - | - | - | - | -12.358 | 39.400 | 235.939 | 509.872 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 131.378 | 243.667 | 190.093 | 388.998 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 378.724 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Reumavision Msk S.r.l.